[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360887-105":59,"doc-detail-360887-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","concomitant-medication-reporting-should-accompany-fecal-microbiota-transplantation-plus-anti-pd-1-therapy-in-gastric-cancer-commentary","Concomitant medication reporting should accompany fecal microbiota transplantation plus anti-PD-1 therapy in gastric cancer - Commentary","","This commentary discusses a phase I study combining fecal microbiota transplantation with anti-programmed cell death protein 1 therapy for refractory microsatellite-stable gastric cancer. The strategy is framed as a pharmacomicrobiomic intervention, not only an immunotherapy pairing. Antibiotics, proton pump inhibitors, corticosteroids, and other microbiome-modifying exposures may alter donor strain engraftment, immune activation, response evaluation, and safety, making standardized concomitant medication reporting essential for interpretability and transferability, especially across China and other Asian clinical contexts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concomitant-medication-reporting-should-accompany-fecal-microbiota-transplantation-plus-anti-pd-1-therapy-in-gastric-cancer-commentary/360887/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concomitant-medication-reporting-should-accompany-fecal-microbiota-transplantation-plus-anti-pd-1-therapy-in-gastric-cancer-commentary/360887.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What strategy does the commentary recommend for FMT plus anti-PD-1 in refractory microsatellite-stable gastric cancer?","Question",{"text":112,"@type":113},"The commentary recommends treating fecal microbiota transplantation plus anti-PD-1 as a pharmacomicrobiomic intervention rather than only as an immunotherapy combination.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is standardized concomitant medication reporting important in these trials?",{"text":117,"@type":113},"Antibiotics, acid suppression, corticosteroids, and other microbiome-modifying exposures can affect donor strain engraftment, immune activation, response assessment, and safety, so incomplete documentation can limit interpretability.",{"name":119,"@type":110,"acceptedAnswer":120},"Which gastric cancer–related concomitant exposures are highlighted as particularly relevant?",{"text":121,"@type":113},"The commentary highlights acid suppression for reflux or post-gastrectomy symptoms, Helicobacter pylori testing or eradication history, perioperative antibiotics, biliary infection, nutritional support, and diarrhea treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360887,1790785298,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":81,"preview_urls":144},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Commentary  \n Concomitant medication reporting  \nshould accompany fecal microbiota transplantation plus anti-PD-1 therapy in gastric cancer  \nGuofu Mao  , Haizhen Lan  \nTo cite: Mao G, Lan H. Concomitant medication reporting should accompany fecal microbiota transplantation plus anti-PD-1 therapy in gastric cancer. Journal for ImmunoTherapy of Cancer 2026;14:e015908 . doi:10 . 1136/ jitc-2026-015908  \nAccepted 24 June 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nDanyang People’s Hospital and Affiliated Danyang Hospital of Nantong University, Danyang, People's Republic of China  \nCorrespondence to  \nDr Guofu Mao; [gl720627@126.com](gl720627@126.com)  \nABSTRACT  \nThis commentary discusses the phase I study of fecal microbiota transplantation plus anti-programmed cell death protein 1 therapy in refractory microsatellite-stable gastric cancer. We suggest that this strategy should be treated as a pharmacomicrobiomic intervention rather than only as an immunotherapy combination. Evidence from fecal microbiota transplantation trials and microbiome immunotherapy studies indicates that antibiotics, proton pump inhibitors, corticosteroids and other microbiomemodifying exposures may affect donor strain engraftment, immune activation, response assessment and safety. In China and other Asian settings, where acid suppression, Helicobacter pylori history, perioperative antibiotic use and nutritional interventions are common, standardized concomitant medication reporting would make future studies more interpretable and transferable.  \nMANUSCRIPT  \nGastric cancer remains a major setting in which immune checkpoint blockade has substantial but uneven clinical activity, particularly in microsatellite-stable disease. The phase I study by Zhang et al is therefore an important early report because it tests whether fecal microbiota transplantation can be combined with anti-programmed cell death protein 1 (PD-1) therapy to improve treatment responsiveness in patients with refractory microsatellite-stable gastric cancer.1 Early trials in melanoma and other solid tumors have shown that fecal microbiota transplantation from immunotherapy-responsive or healthy donors can reshape the gut microbiome, support donor-derived microbial engraftment and restore or enhance antiPD-1 sensitivity in a subset of patients.2–4  \nAs this approach moves from proof of concept to larger studies, we believe that fecal microbiota transplantation plus antiPD-1 therapy should be viewed not only asa biologic immunotherapy strategy but also as a pharmacomicrobiomic intervention. Its apparent efficacy may be influenced by  \nmedications and supportive care measures that alter microbial ecology, mucosal immunity or systemic immune tone. If these exposures are incompletely recorded, donor strain engraftment, immune response and safety findings may be difficult to interpret. This concern is supported by cross-disease metagenomic evidence showing that donor strain engraftment after fecal microbiota transplantation is variable and is shaped by clinical and treatment-related factors rather than by donor material alone.5  \nThis issue is particularly relevant in gastric cancer. Patients often receive acid suppression for reflux symptoms, ulcer risk, post-gastrectomy symptoms, dyspepsia or chemotherapy-related gastrointestinal discomfort. Many also have a history of Helicobacter pylori testing or eradication, perioperative antibiotic exposure, biliary infection, nutritional support or treatment for diarrhea. These are not minor background variables ina microbiome-directed trial. The evidence base of the influence of concomitant medications in patients with gastric cancer receiving fecal microbiota transplantation and antiPD-1 therapy is still in development, but available studies already show why careful covariate control is needed. In melanoma, fecal microbiota transp","cbCaisRq5cYvKTCq","https://ap.wps.com/l/cbCaisRq5cYvKTCq","pdf",204733,"English","# Abstract\n# Manuscript\n## Rationale for combining FMT with anti-PD-1\n## Pharmacomicrobiomic framing and variability of donor engraftment\n## Relevance to gastric cancer concomitant exposures\n## Table 1: Medication and supportive-care exposures to report","[{\"question\":\"What strategy does the commentary recommend for FMT plus anti-PD-1 in refractory microsatellite-stable gastric cancer?\",\"answer\":\"The commentary recommends treating fecal microbiota transplantation plus anti-PD-1 as a pharmacomicrobiomic intervention rather than only as an immunotherapy combination.\"},{\"question\":\"Why is standardized concomitant medication reporting important in these trials?\",\"answer\":\"Antibiotics, acid suppression, corticosteroids, and other microbiome-modifying exposures can affect donor strain engraftment, immune activation, response assessment, and safety, so incomplete documentation can limit interpretability.\"},{\"question\":\"Which gastric cancer–related concomitant exposures are highlighted as particularly relevant?\",\"answer\":\"The commentary highlights acid suppression for reflux or post-gastrectomy symptoms, Helicobacter pylori testing or eradication history, perioperative antibiotics, biliary infection, nutritional support, and diarrhea treatment.\"}]","Concomitant medication reporting should accompany fecal microbiota transplantation plus anti-PD-1 therapy in gastric cancer - Commentary | PDF",1790141929,[145,149,153],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df00af24b723acb5a6720b18602cd628.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8be8e2ed0157e84636c793499de1a720.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dce6de96b23a3099ffcff3dad771c8f0.webp",981,1308]